{"name":"Milestone Pharmaceuticals Inc.","slug":"milestone-pharmaceuticals-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":18108000,"netIncome":-63058000,"cash":73046000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Etripamil NS","genericName":"Etripamil NS","slug":"etripamil-ns","indication":"Acute conversion of supraventricular tachycardia to normal sinus rhythm","status":"phase_3"}]}],"pipeline":[{"name":"Etripamil NS","genericName":"Etripamil NS","slug":"etripamil-ns","phase":"phase_3","mechanism":"Etripamil is a rapid-onset, short-acting calcium channel blocker administered as a nasal spray that slows heart rate and reduces blood pressure by blocking L-type calcium channels in cardiac and vascular tissue.","indications":["Acute conversion of supraventricular tachycardia to normal sinus rhythm"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxPOHkyNWlscGo4UW5ITXdES2wwMGNDYzVFVV9MWGVreWNzekdRRTlfbUtMdlllaHRmTlRUSm1lZzloaThvVWRoMTA4cGJud3J2MXE0MXBCVjNUN2N0RVVibkhyTy1ldk9MSkZodmgyQXVjcTRhM1FIbG1SSXUzN294anNzQmNOOFo4YVdWRm5wWEo1X3JaWnExa1dzc0RBTkFoQzN0Q29WYXBjOF9ad2dHcVFscXNmQmFTYjNzR0RuV2pNQm5KNzA1RllRZw?oc=5","date":"2026-03-23","type":"pipeline","source":"Stock Titan","summary":"Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option - Stock Titan","headline":"Milestone Pharmaceuticals Inc. (MIST) GC reports 400,000-share stock option","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPekw4Y3c2Nmd3aGxITUlYeWVCdGloNmdxc19uVmxXU3hINXdOTWZzZkQxSDRlTmlLLUYya3pxajMyMm5lN2VjX2p2YWtNZzk4ZWVsRVBvekZRQUdQTV9wd1JsTm8xZlBIOUxtanEyX2gzOTFGbExBVzJvRlR6UktxTEpiLXdJTE9oSDV6VWFiT2ppTFhJWXQybWVkTjFHdFQtcWoxcTZ4WjRlUQ?oc=5","date":"2026-03-20","type":"pipeline","source":"Benzinga","summary":"Why Milestone Pharma Stock Is Taking A Dive Today - Milestone Pharmaceuticals (NASDAQ:MIST) - Benzinga","headline":"Why Milestone Pharma Stock Is Taking A Dive Today - Milestone Pharmaceuticals (NASDAQ:MIST)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxOUFdkY01tVUctLVZFOUhSdE9aQ2lWWkRyX2lVZU1JemNtNGRyU0NaUE9YWVphTmJZOWNlaFA3aW5vYVZBV1JfVWxVanJlWkFGWGFPMl9QN3JsN3UxRlBUSjlmQ09EQTJoM3pLZ2VKSHNPb0pIclRCODQ3aWlSdFhzak00U3F2N2RNeEE?oc=5","date":"2026-03-20","type":"earnings","source":"StocksToTrade","summary":"Milestone Pharma Faces Earnings Hurdles Amidst Market Fluctuations​ - StocksToTrade","headline":"Milestone Pharma Faces Earnings Hurdles Amidst Market Fluctuations​","sentiment":"neutral"},{"date":"2026-03-20","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2026-03-20","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxOQTg5Q3FBcllfVFVqQjhYVmtHSUZJZnNMVlZrREJ4TFptN0lMSzdRRnhTX3ZNV1RYU1ItYzhydnJJMmdJV1pRZTZHT0pwak1qcGJDWDlfZFotcWRxM3hMRTJ2SlA4MUpHNS1mMVJ5SUFfdXh1cmtuNFFrYmNxX09CZFBDWGQ2Y1JsZm9JZEtOZHFYSmRrME9KSC1tYw?oc=5","date":"2026-03-12","type":"earnings","source":"Yahoo Finance","summary":"Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026 - Yahoo Finance","headline":"Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxPblFET1pxR0REWWdKQzVheTFTMVZwWTVxUzloSi1wenNhR1NydWlzWnB2ZVBiUDYzMzY0SWxqdjd5cndrakZOMmRRS1gwYXF5S2hMTEg1X0JxV1dBQlBxa1JlS0NWWWE1Mk5nSHlCUG1JdE1ZWmxKMUd2aktwMjE4N0UtX0Y4dGY4aHdMOXVUSFFQbnYwWUs5UnhPbGs4RmVSbWtBX1pneXJka2VMWFVDNmR2VlIzeGk4QTZ0ZHh3?oc=5","date":"2026-03-12","type":"pipeline","source":"Stock Titan","summary":"Milestone Pharma sets Mar. 20 call to review 2025 results - Stock Titan","headline":"Milestone Pharma sets Mar. 20 call to review 2025 results","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-26","type":"regulatory","source":"GlobeNewswire","summary":"Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tac","headline":"Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Appr","sentiment":"positive"},{"date":"2026-01-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxPTENjOTEwTjBBNzhRUWxOMDlvbkhiMmdCZGk1MFJ3YzRreGRTZS1sYWY4SEYzVUV3WnhDc25JTDdnSFdfRG9VN09zeDJ3NFlwVHZHZkVOX3RHdlR0WlBXYnFONTE1OGUzY0R6ZmNYUmNCRjI5QmNaNG5xak16Ry1GVHhOVFZONFEzNUU0LTBXaWZrNkk4WWJZRTdfSmtXS0czUnlRelFVSnpLcVpMMWdLOTB2S0dacUR0b09nYw?oc=5","date":"2026-01-15","type":"regulatory","source":"Seeking Alpha","summary":"Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST) - Seeking Alpha","headline":"Milestone Pharmaceuticals: Selling The News On Cardamyst Approval Makes No Sense (MIST)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxNaW5Od0NyckNBZy1vcVhrNkJndUVCanZLUm5hWUljbklyejJzbnV1WUFBZjlnMnJvckEzbTYwcGMxOFU5aUcxemo4QnNtZlFOOEx4Q0JSZDNhN2lKU21iRjUzbDAydlJHR01iN2xMTDVCaEhfclRyd3lDU1EwRjZPWXZZcXpwbUVRMjNzTGFIdnBNck82akF6RVRyTlNGUGZxQ1NabElQMUFvY1BrZ1VHVDNrcXkzN2RXQ0RFQWxLa0pWamI0UDRsekhzemZlQQ?oc=5","date":"2025-12-15","type":"regulatory","source":"TechStock²","summary":"Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025) - TechStock²","headline":"Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi1gJBVV95cUxNSWdSc3ZnTTJMTVdtS0hWSVNlejRTcEJUZjFzUXZ4RUkwNkhlRTFlWjdTYThFRUhja2gzc3BYTEZHUVNMVG5CdHFRQjlyaVA5cTVGU1pRWUpRZzhPejBRRmU0cDF6SVBVRVN6NWJrcXFPQklpR2Nvck90QU9PM0hHVXJQcU1sbjRua0RMTFpyM3F5QUhsZ21vaC0tUXBzZm00WVBfSFhlbTRrU3RLSy00dXhTN2RXcXZnRlNCWjIxLV9yaTlZckFocDkyYTlhQ1pSY2R6eUd4TDdxcUlUQS1odGZjRERfZXo3LU45UXFxT0Zvc0xWaHNJeWJNa1dRaWo1bXRpbFl6R2g5MWpSUl9PTUE5UWhpenAzbGhNR25XTUlPQ3BNZ041UGRzVDdiR1pTQTUwb2UtOG40a1Q5Zk9XOVY5V3NwSzhiaDlaVHhwUldsYUIzaUE?oc=5","date":"2025-12-12","type":"regulatory","source":"GlobeNewswire","summary":"Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) - GlobeNewswire","headline":"Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults wit","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxOdWdyVWUxdTVVdHhnYlQwdFlTMDhVOGpRZ1lDZnBQZHJSeFkwMVVfSTh6ZEc4Ym5CTVR3Qk9Ic1paZW1GdDQyQ1JVMndvNzZqczJGdWhLaUhtZmswX0V2YXFRb2I5WnZPdHlzTDN6dHhWdlRaSDJHQVNHNFl6djBmVE93Q1l3MV92SFNLX3p3?oc=5","date":"2025-12-11","type":"regulatory","source":"timothysykes.com","summary":"Milestone Pharmaceuticals Eyes FDA Approval Amid Strong Q3 Results - timothysykes.com","headline":"Milestone Pharmaceuticals Eyes FDA Approval Amid Strong Q3 Results","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxOMzlWelZFME9mT1pBUEllZ1lXblpEaFZnMmJpMDdxaHZ6QTZ5cDQ4cEFyWkRyTEhFNzluRmtFanlyZmQ2bXpVcU1YQW56MmNNZEllSEFoUUtZRFNJUHBucHdCOWJCUG1EcXB0Y1BaZE0tcmtESVRpSVRvcTRxdDd6YTFGNWVadWZVRzluMUFISHZrYXNZaU9z?oc=5","date":"2025-11-25","type":"pipeline","source":"Yahoo Finance","summary":"Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects - Yahoo Finance","headline":"Jefferies Lifts Milestone Pharmaceuticals (MIST) Price Targets on Product Sales Prospects","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxNdjdoU3NCWk5Ed3hRMFNNel9QeUY5cXNCX2p0UVRham1GRG9ld1ZPdThOVjRockFMNld0R3FfT1BZNWZwd2xzb00wUjVCX1p6SG1KUGtsTDJxZ0VrUXFSbUZJZ2FvQVRQX0xldjZhRDZYZHk4ZnloeTRMUDFIbi1NRlVtQlhJdkRpTWllVlhfaWx6VlBKaVBnRUlPd2FrZWhhNmlFaXQxYzczMHYwSWVDRmxEQmhGRGxWLWJF?oc=5","date":"2025-07-18","type":"regulatory","source":"Seeking Alpha","summary":"Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution (MIST) - Seeking Alpha","headline":"Milestone Pharmaceuticals Remains A Buying Opportunity Despite Recent Dilution (MIST)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":18108000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-63058000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":73046000,"cashHistory":[],"totalAssets":113561000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}